Valvular Heart Disease Treatment Market

Valvular heart disease is characterized by damage to or a defect in one of the four heart valves namely the mitral valve, aortic valve, tricuspid valve, and pulmonary valve.
Valvular Heart Disease Treatment Market contains market size and forecasts of Valvular Heart Disease Treatment in Global, including the following market information:
Global Valvular Heart Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Valvular Heart Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cardiac Catheterization Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Valvular Heart Disease Treatment include Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corp., Medtronic, CryoLife Inc., Edwards Lifesciences Corporation, LivaNova PLC, Neovasc Inc. and Micro Interventional Devices, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Valvular Heart Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:

• Cardiac Catheterization
• Electrocardiogram (ECG)
• Chest X-Ray
• Stress Test
• Others

• Hospital & Clinics
• Ambulatory Surgical Centers
• Research Institutes

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

• Key companies Valvular Heart Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Valvular Heart Disease Treatment revenues share in global market, 2021 (%)

• Abbott Laboratories
• B. Braun Melsungen AG
• Boston Scientific Corp.
• Medtronic
• CryoLife Inc.
• Edwards Lifesciences Corporation
• LivaNova PLC
• Neovasc Inc.
• Micro Interventional Devices
• Symetis SA
• Jenavalve Technology
• TTK Healthcare Limited
• Colibri Heart Valve
• Lepu Medical Technology Co.
• Braile Biom?dica